Suppr超能文献

胸科移植受者从其他唑类药物转换为艾沙康唑时免疫抑制剂剂量需求的差异。

Difference in immunosuppressant dose requirement when transitioning to isavuconazole from other azoles in thoracic transplant recipients.

作者信息

Kozuch Jade M, Burt Carrie, Afshar Kamyar, Aslam Saima, Yung Gordon, Mariski Mark, Golts Eugene, Feist Ashley

机构信息

Department of Pharmacy, University of California San Diego, La Jolla, California, USA.

Department of Pharmacy, Scripps Memorial Hospital, La Jolla, California, USA.

出版信息

Transpl Infect Dis. 2024 Feb;26(1):e14209. doi: 10.1111/tid.14209. Epub 2023 Dec 7.

Abstract

The triazole antifungal isavuconazole (ISAVU) is used for prevention and treatment of fungal infections in solid organ transplant (SOT). SOT recipients commonly need to transition from one azole to another due to breakthrough infection, toxicity, or other reasons. The purpose of our study was to evaluate the effect of ISAVU on immunosuppressant concentrations in thoracic transplant recipients when ISAVU was started de novo or transitioned from another azole. We conducted a single-center retrospective cohort study including 68 patients (51 lung, 14 heart, and 3 heart/lung transplant). Concentration to dosage ratios (C/D) of immunosuppressants were assessed at baseline, day 3, and weekly for 9 weeks. When starting ISAVU de novo, we observed a temporary doubling of tacrolimus exposure. Cyclosporine and sirolimus required dose decreases. Tacrolimus C/D increased by 110% at day 3 in patients started on ISAVU de novo then returned to baseline C/D ± 17% weeks 2-9 (n = 8). One cyclosporine patient started on ISAVU de novo had variable C/D, and C/D increased by 219% ± 72% in 2 sirolimus patients. When transitioning from other azoles, tacrolimus and cyclosporine required about twice the initial dose. After week 1, tacrolimus C/D decreased by 53% ± 6% in patients transitioned from posaconazole (n = 33), voriconazole (n = 14), or fluconazole (n = 2). Cyclosporine C/D decreased by 45% ± 16% in patients transitioning from other azoles (posaconazole [n = 2], voriconazole [n = 2], fluconazole [n = 1]). Sirolimus C/D decreased by 73% ± 13% in patients transitioned from posaconazole (n = 7). Aside from the initial loading phase, ISAVU had a lesser degree of interaction with immunosuppressants than other azoles in loading phase, ISAVU had a lesser degree of interaction with immunosuppressants than other azoles in adjustments for the 4-week period after initiating antifungal therapy with ISAVU or switching from another agent.

摘要

三唑类抗真菌药艾沙康唑(ISAVU)用于实体器官移植(SOT)受者真菌感染的预防和治疗。由于突破性感染、毒性或其他原因,SOT受者通常需要从一种唑类药物转换为另一种。我们研究的目的是评估艾沙康唑初治或从另一种唑类药物转换时对胸科移植受者免疫抑制剂浓度的影响。我们进行了一项单中心回顾性队列研究,纳入68例患者(51例肺移植、14例心脏移植和3例心肺联合移植)。在基线、第3天以及之后9周每周评估免疫抑制剂的浓度与剂量比(C/D)。初治艾沙康唑时,我们观察到他克莫司暴露量暂时加倍。环孢素和西罗莫司需要减少剂量。初治艾沙康唑的患者在第3天时他克莫司C/D增加了110%,然后在第2 - 9周恢复到基线C/D±17%(n = 8)。1例初治艾沙康唑的环孢素患者C/D变化不定,2例西罗莫司患者C/D增加了219%±72%。从其他唑类药物转换时,他克莫司和环孢素所需初始剂量约为原来的两倍。第1周后,从泊沙康唑(n = 33)、伏立康唑(n = 14)或氟康唑(n = 2)转换而来的患者中,他克莫司C/D下降了53%±6%。从其他唑类药物(泊沙康唑[n = 2]、伏立康唑[n = 2]、氟康唑[n = 1])转换而来的患者中,环孢素C/D下降了45%±16%。从泊沙康唑(n = 7)转换而来的患者中,西罗莫司C/D下降了73%±13%。除了初始负荷期外,在开始使用艾沙康唑抗真菌治疗或从其他药物转换后的4周调整期内,艾沙康唑与免疫抑制剂的相互作用程度低于其他唑类药物。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验